2022
N-Palmitoyl-D-Glucosamine Inhibits TLR-4/NLRP3 and Improves DNBS-Induced Colon Inflammation through a PPAR-α-Dependent Mechanism
Abstract: Similar to canine inflammatory enteropathy, inflammatory bowel disease (IBD) is a chronic idiopathic condition characterized by remission periods and recurrent flares in which diarrhea, visceral pain, rectal bleeding/bloody stools, and weight loss are the main clinical symptoms. Intestinal barrier function alterations often persist in the remission phase of the disease without ongoing inflammatory processes. However, current therapies include mainly anti-inflammatory compounds that fail to promote functional s…
Search citation statements
Paper Sections
Select...
18
7
6
2
Citation Types
2
25
0
0
Year Published
Range
2022
2026
Publication Types
Select...
24
1
1
Relationship
1
25
Authors
Journals
Cited by 26 publications
(27 citation statements)
References 52 publications
2
25
0
0
Smart CitationsHow the paper below cites the one you are viewing
“…The data further reveal that in our experimental conditions mPGA effect is independent from the glucosamine (monosaccharide portion of PGA), since glucosamine alone showed no beneficial effect in any of the studied parameters. In line with previous findings (Palenca et al, 2022), the effects of mPGA are mediated through agonism at the PPARα receptors. This is underscored by the nearly complete abolition of mPEA protective effects in our carcinogenesis model upon co‐administration of MK866.…”
Section: Discussion
supporting
confidence: 93%
N‐palmitoyl‐
d
‐glucosamine limits mucosal damage and
VEGF
‐mediated angiogenesis by
PPARα
‐dependent suppression of
pAkt
/
mTOR
/
HIF1α
pathway and increase in
PEA
Phytotherapy Research
Self Cite
Abstract